Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Cequent Seeks First Oral RNAi Trial
|
Luke Timmerman |
11/12/09 |
Boston
|
|
Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target
|
Luke Timmerman |
11/11/09 |
Boston
|
|
RXi Replaces CEO
|
Luke Timmerman |
11/06/09 |
Boston
|
|
Cequent Pharmaceuticals, With First Oral RNAi Drug Soon to Enter Humans, Raises $3.4M
|
Luke Timmerman |
10/30/09 |
Boston
|
|
Why Big Pharma Wants To Be Like Big Biotech
|
Stewart Lyman |
08/19/09 |
National
|
|
Alnylam, Tekmira and New Northwest Firm, AlCana, Push Boundaries of RNAi Delivery
|
Luke Timmerman |
08/13/09 |
Boston
|
|
Alnylam Takes Moment to Pause on Cutting Edge, Mull Options on RSV Game Plan
|
Luke Timmerman |
08/11/09 |
Boston
|
|
Microsoft Sells Razorfish, EnerG2 Scores Stimulus Funds, Tekmira Teams Up with Alnylam, & More Seattle-Area Deals News
|
Gregory T. Huang |
08/11/09 |
Seattle
|
|
RXi Announces $8.3M Offering
|
Wade Roush |
07/31/09 |
Boston
|
|
RXI Licenses RNAi Delivery Mode
|
Luke Timmerman |
07/27/09 |
Boston
|
|
Dicerna, Archemix Team Up to Make Souped Up RNAi Combo Drugs
|
Luke Timmerman |
07/21/09 |
Boston
|
|
Cell Therapeutics Ships App to FDA, Targeted Genetics Cuts Again, Sanofi CEO Looks to Biotech & More Seattle Area Life Sciences News
|
Luke Timmerman |
06/25/09 |
Seattle
|
|
Amazon Buys SnapTell, Madrona Backs Animoto, MDRNA Works Out Tech License, & More Seattle-Area Deals News
|
Gregory T. Huang |
06/23/09 |
Seattle
|
|
AVI Developing Swine Flu Drugs
|
Luke Timmerman |
06/22/09 |
Seattle
|
|
MDRNA Gains Full Rights to Drug Technology
|
Luke Timmerman |
06/19/09 |
Seattle
|
|
UW Stem Cell Startup is Born, Global Health’s “Davos” Arrives, MDRNA Unloads Debt, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
06/18/09 |
Seattle
|
|
MDRNA Pays Off $5.5M Debt
|
Luke Timmerman |
06/16/09 |
Seattle
|
|
Dendreon Resists Urge to Sell Out, NanoString Nabs $30M, VC Firm Cashes Out on OncoGenex, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
06/11/09 |
Seattle
|
|
MDRNA Raises $10.5M
|
Luke Timmerman |
06/10/09 |
Seattle
|
|
MDRNA Nasal Spray Gets FDA Nod
|
Luke Timmerman |
06/09/09 |
Seattle
|
|
Aileron Snags $40M From Quartet of Pharma Giants to Develop New Class of Drugs
|
Luke Timmerman |
06/08/09 |
Boston
|
|
AVI Gets $3M For Muscular Dystrophy
|
Luke Timmerman |
06/04/09 |
Seattle
|
|
Vulcan’s Biotech Windfall, Tekmira Tackles RNAi Delivery, The $1,000 Genome Debate, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
05/28/09 |
Seattle
|
|
Tekmira Tackles RNAi Delivery Challenge, With Alnylam, Roche Putting It to the Test
|
Luke Timmerman |
05/26/09 |
Seattle
|
|
MDRNA Shrinks Board of Directors
|
Luke Timmerman |
05/21/09 |
Seattle
|
|
Targeted Genetics Faces Extinction, Cell Therapeutics Unloads Debt, Dendreon Raises $221M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
05/14/09 |
Seattle
|
|
Tekmira Nabs $50M RNAi Deal
|
Luke Timmerman |
05/11/09 |
Seattle
|
|
AVI Wins Part of $2.5M Contract
|
Luke Timmerman |
05/06/09 |
Seattle
|
|
Oral RNAi Drug Stops Inflammation in Mice, RXi Says
|
Luke Timmerman |
04/30/09 |
Boston
|
|
Ebola Fighter AVI Biopharma Gears Up for Biodefense Contracts
|
Luke Timmerman |
04/29/09 |
Seattle
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
